Join
Live feed
·
NEWSReleasevia Quantisnow
NeuroSense Therapeutics Ltd. logo

NeuroSense Announces New Data Analysis From PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing Of Disease Progression In High-Risk ALS Patients; PrimeC Slowed Disease Progression By 43% In Pre-Specified High-Risk ALS Patients

ByQuantisnow·Wall Street's wire, on your screen.
NRSN· NeuroSense Therapeutics Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NRSN (NeuroSense Therapeutics Ltd.) and more on Quantisnow.

NeuroSense Announces New Data Analysis From PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing Of Disease Progression In High-Risk ALS Patients; PrimeC Slowed Disease Progression By 43% In Pre-Specified High-Risk ALS Patients | Quantisnow